Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...
The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the signaling of interleukin (IL)-31.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback